High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favourable research funding scenario for development of cancer screening tests are key factors contributing to high CAGR of Cervical Cancer Diagnostic during forecast period.
Market Size – USD 6.81 Billion in 2018, Market Growth - CAGR of 6.2%. Market Trends – Product launches and research for Cardiac biomarkers.
According to the current analysis of Reports and Data, the global Cervical Cancer Diagnostic market was valued at USD 6.81 Billion in 2018 and is expected to reach USD 11.00 Billion by year 2026, at a CAGR of 6.2%.
According to the Centres for Disease Control and Prevention (CDC), six million people in the United States acquire HPV each year. At least 20 million already have it, and more than half of all sexually-active adults are expected to be infected during their lifetime. Cervical Cancer is a type of cancer which occurs in the lower part of the uterus which is connected to the vagina. Most of cervical cancer cases are caused by various strains of the human papillomavirus (HPV) which is a sexually transmitted infection. Vaginal bleeding, watery bloody discharge ad pelvic pain during intercourse are the symptoms of cervical cancer. Cervical Cancer can be diagnosed with the help of screening tests like Pap test, HPV DNA test, punch biopsy and endocervical curettage to treat two types of cancer i.e. Squamous cell cancers and Adenocarcinoma.
Increasing adoption of Pap test, huge amount of government funding, increase in occurrence of cervical cancer in middle age women which leads to increase in number of screening, and increase in awareness are some of the primary growth stimulants for the market. For instance, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening, every two years. These programs were found to be responsible for the growth of the overall market. Certain manufacturing and pharmacological issues and regulatory hurdles are hindering the growth of the market.
Increased FDA approval to companies is also propelling the growth of this market. For instance, in June 2018, FDA approved Bevacizumab (Avastin) of Genetech/Roche Inc plus chemotherapy for treating advanced cervical cancer patients.
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/press-release/global-cervical-cancer-diagnostic-market
Further key findings from the report suggest:
- Cervical Cancer Diagnostic market is fastest growing at a CAGR of 2% in Asia Pacific due to high awareness and access to modern healthcare infrastructure, low cost of VIA test and rise in consumption levels.
- The market for point of care testing type segment is expected to hold the fastest growing CAGR because of increase in demand for speedy monitoring patients by doctors and clinicians.
- Europe is the second largest region with a share of 25.8% due to the high cases of cervical disorders in France, Germany, and United Kingdom etc.
- HPV Testing is accounted to be the second leading segment which holds a market share of 25.4% due to high usage for advanced diagnostics and cost effective procedures.
- Diagnostic Centres segment is projected to have the highest CAGR among the other end user type.
- North America is expected to account for the 45.6% of the global Cervical cancer Diagnostic market owing to the increasing occurrence of cervical cancer cases, rise in female population, growing acceptance of HPV infections along with government funding scenario.
- Radiation Therapy segment holds the second largest share in this market which is valued at USD 2123.6 million due to its expensive manufacturing cost but people prefer it because it kills cancer cells at one go.
- Key participants include Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company and F. Hoffmann-La Roche Ltd.
Segments covered in the report:
For the purpose of the study, this Reports and Data has segmented the Global Cervical Cancer Diagnostic Market on the basis of biomolecule type, disease type, profiling technologies, application, services and the regional outlook:
Product Type (Revenue, USD Million; 2016–2026)
- Pap Smear Tests
- Colposcopy
- HPV Testing
- Biopsy & Endocervical Curettage
- Others
Therapy (Revenue, USD Million; 2016–2026)
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
End User (Revenue, USD Million; 2016–2026)
- Hospitals & Clinics
- Diagnostic Centres
- Laboratories
- Others
Regional Outlook: (Revenue, USD Million; 2016–2026)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Spain
- France
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
Request
for FREE sample copy of this premium report at:
About Us:
We are a boutique market intelligence and strategic consulting firm dedicated to make an meaningful impact on businesses across the globe. Our stellar estimation and forecasting models have earned recognition across majority of the business forum across the globe. Our services are arrayed over diverse sectors and industries looking to expand in alternative regions and products.
Contact Us:
John Watson
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
We are a boutique market intelligence and strategic consulting firm dedicated to make an meaningful impact on businesses across the globe. Our stellar estimation and forecasting models have earned recognition across majority of the business forum across the globe. Our services are arrayed over diverse sectors and industries looking to expand in alternative regions and products.
Contact Us:
John Watson
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
No comments:
Post a Comment